SiteOne Therapeutics
SiteOne Therapeutics: SF-based innovators in pain treatment, developing selective Naᵥ1.7 inhibitors.
Founded
2010SiteOne Therapeutics: SF-based innovators in pain treatment, developing selective Naᵥ1.7 inhibitors.
Founded in San Francisco, SiteOne Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics and diagnostics for the treatment of acute and chronic pain. Their core mission is to provide safe, effective, and efficient alternatives to existing pain therapies, such as NSAIDs and opioids. The company's lead products are highly selective inhibitors of the voltage-gated sodium ion channel Naᵥ1.7, which is crucial in pain signal generation and conduction. SiteOne Therapeutics focuses on addressing hypersensitivity disorders through innovative solutions.
SiteOne Therapeutics has garnered attention from notable investors and industry experts due to its groundbreaking approach to pain management. The company's key achievements include advancing their lead therapeutic candidates through various stages of clinical development, demonstrating significant potential in preclinical trials. By targeting Naᵥ1.7 with high specificity, SiteOne aims to mitigate the side effects associated with traditional pain medications, potentially transforming the landscape of pain treatment and improving the quality of life for millions of patients worldwide.
Companies similar to SiteOne Therapeutics include Doloromics, Sarentis Therapeutics, NeuroTherapeutics Pharma and Regulonix Holding.
SiteOne Therapeutics was founded in 2010.
SiteOne Therapeutics' headquarters is located in Bozeman, MT, US.
SiteOne Therapeutics' most recent funding round was for $15M (USD) in May 2023.
As of May 18, 2023, SiteOne Therapeutics has raised a total of $34.2M (USD).
SiteOne Therapeutics has 5 employees as of Feb 4, 2024.
NeuroTherapeutics Pharma
